In this issue:
Pathological CR-adapted dual HER2 blockade for early breast cancer
Tucatinib-trastuzumab-deruxtecan for HER2+ metastatic breast cancer
Socioecological factors and racial differences in breast cancer recurrence scores
Hyperbaric oxygen for late local toxic effects after breast RT
Trastuzumab deruxtecan vs. physician's choice in HER2+ metastatic breast cancer
Mortality risks in men with hormone receptor-positive breast cancer
Sacituzumab govitecan vs. trastuzumab deruxtecan in breast cancer brain metastases
Neoadjuvant cabazitaxel vs. paclitaxel in TNBC/luminal B/HER2– breast cancer
Metformin/lifestyle intervention: effects on adipokines and hormones in breast cancer survivors
Adjuvant abemaciclib dose reductions in high-risk early breast cancer
Please login below to download this issue (PDF)